Medication info
Posiromet Extended-Release 5/500 mg (Dapagliflozin, Metformin Hydrochloride)

Posiromet Extended-Release 5/500 mg (Dapagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletDapagliflozin Propanediol Hydrate›6.15mg / 1 tablet
Manufacturer / importer
Daewoong Pharmaceutical Co., Ltd.
Appearance
Orange, rectangular extended-release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP) x 5]
Approval status
Active

MFDS item code 202300297 · Approved 2023.01.18 · Insurance code 641608030

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received pharmacological treatment for diabetes and whose glycemic control is inadequate with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce the gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same dose of metformin the patient was taking or a therapeutically appropriate dose close to it. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and dose adjustment made as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and dose adjustment made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Because changes may affect glycemic control, any change in treatment in patients with type 2 diabetes mellitus should be made under careful monitoring. This medicine should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling the tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher but less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an active ingredient in this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Daewoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

View approved original text

This medication is used to assist in blood sugar control for adult patients with type 2 diabetes through the combined administration of dapagliflozin and metformin. It can be effectively used along with dietary and exercise therapies to improve blood sugar levels. Moreover, for type 2 diabetes patients who have difficulty controlling blood sugar or have existing cardiovascular diseases or risk factors, it is advised to consult with a specialist as dapagliflozin may impact the occurrence of cardiovascular events. This medication helps to improve blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received pharmacological treatment for diabetes and whose glycemic control is inadequate with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce the gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the same dose of metformin the patient was taking or a therapeutically appropriate dose close to it. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and dose adjustment made as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release metformin to the extended-release formulation, glycemic control should be closely monitored and dose adjustment made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering agents. Because changes may affect glycemic control, any change in treatment in patients with type 2 diabetes mellitus should be made under careful monitoring. This medicine should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling the tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher but less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an active ingredient in this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions, 9. Administration to Elderly Patients).

Precautions

This medication contains metformin hydrochloride and dapagliflozin and is primarily used for blood sugar control in patients with type 2 diabetes. Severe lactic acidosis, a rare side effect, may occur while taking this medication, so patients with impaired kidney function, serious infections, or dehydration should be particularly cautious. Additionally, when taken with insulin or sulfonylureas, the risk of hypoglycemia may increase, so dosage adjustments may be necessary if taking these medications together. Patients with moderate to severe kidney impairment, liver dysfunction, acute conditions like myocardial infarction or sepsis, and patients with type 1 diabetes should not use this medication. Patients scheduled for surgery or receiving radiological contrast agents should temporarily discontinue this medication 48 hours before the procedure or examination, and resume only after confirming normal kidney function. This medication can cause decreased fluid volume and hypotension, thus elderly patients, those taking diuretics, and patients with cardiovascular diseases need to exercise extra caution when taking it. During treatment, infections such as genital infections or urinary tract infections may occur; any related symptoms should be reported to a healthcare professional immediately. The metformin component can lower vitamin B12 levels, so checking vitamin B12 concentrations regularly during long-term treatment is advisable. Pregnant or potentially pregnant women, as well as breastfeeding women, should not take this medication, and if pregnancy is confirmed, should discontinue immediately. Excessive alcohol consumption can increase the risk of side effects associated with this medication, so caution is advised. Dizziness or hypoglycemic symptoms may occur while taking this medication, so caution is needed when driving or operating machinery. Finally, this medication should be kept out of reach of children and stored in its original container to prevent misuse or degradation of quality.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 82 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • vitamin B12 decrease/deficiency
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbance
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • benign prostatic hyperplasia
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss
  • acute cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. A storage temperature between 1 to 30 degrees Celsius at room temperature is recommended to maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Orange, rectangular extended-release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP) x 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.